Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO

Cancer diagnostics firm Caris Life Sciences is targeting a valuation of up to $5.35 billion in its U.S. IPO, offering 23.5 million shares priced between $16 and $18 to raise up to $423.5 million. Backed by Sixth Street, Caris specializes in precision oncology, competing with firms like Roche’s Foundation Medicine and Guardant Health, and will trade on the Nasdaq under the symbol "CAI"; Neuberger Berman has indicated interest in purchasing up to $75 million in shares.

Analysis

Caris Life Sciences is pursuing a U.S. initial public offering with a target valuation of up to $5.35 billion, planning to raise up to $423.5 million by offering 23.5 million shares priced between $16 and $18 each. The Irving, Texas-based precision oncology firm, backed by Sixth Street and J.H. Whitney, specializes in tumor profiling and has recently launched blood-based cancer diagnostics, having conducted over 6.5 million tests on 849,000 cases. This move comes as the IPO market shows signs of recovery from earlier tariff-related volatility, exemplified by the strong post-IPO performance of Tempus AI, whose shares have risen 67.8% since its offering. Notably, Caris's current IPO valuation target is considerably lower than the $7.83 billion valuation it achieved in a 2021 funding round led by Sixth Street, suggesting a potential market recalibration. Investment management firm Neuberger Berman has indicated interest in purchasing up to $75 million of shares in the offering. Caris, which competes with entities such as Roche’s Foundation Medicine, Guardant Health (GH), and Grail, and partners with biopharma companies like Moderna (MRNA), AbbVie (ABBV), and Xencor (XNCR), will trade on Nasdaq under "CAI", with CEO David Halbert expected to retain approximately 41.7% ownership post-IPO.

Key Decisions for Investors

• Investors should evaluate the IPO valuation of up to $5.35 billion, which is significantly below Caris's 2021 private valuation of $7.83 billion, potentially offering a more attractive entry point or reflecting adjusted market expectations for growth and profitability in the diagnostics sector.
• Consider the positive indicators such as the resurgent IPO market, the successful listing and subsequent 67.8% share price increase of comparable firm Tempus AI, and Neuberger Berman's indicated $75 million investment interest, alongside the inherent risks of a competitive landscape.
• Monitor the company's ability to scale its recently launched blood-based molecular profiling services, its performance relative to established competitors like Guardant Health, and assess the impact of the CEO's substantial post-IPO ownership stake of 41.7% on corporate governance and strategy.